At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
Bevacizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ML21206 - Bevacizumab in Chronic Lymphocytic Leukemia: A Proof of Concept Study
In Brief
A Phase 2 clinical trial evaluating Bevacizumab for Lymphocytic Leukemia, Chronic. Completed, enrolled 2 participants across 1 site.
Detailed Summary
This single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with Avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. Patients received 8 cycles (21 days duration) of Avastin monotherapy (15mg/kg) with 6 months of follow-up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphocytic Leukemia, Chronic
CountriesAustria
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedSep 2008
Primary CompletionMar 2009
TodayJul 2026
First PostedSep 18, 2008
Enrollment StartSep 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.8 years ago
Interventions
Bevacizumabdrug
Bevacizumab was supplied as a sterile liquid in single-use vials.